Literature DB >> 15346048

VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI.

Bang H Hoang1, Jonathan P Dyke, Jason A Koutcher, Andrew G Huvos, Hiroo Mizobuchi, Beth Anne Mazza, Richard Gorlick, John H Healey.   

Abstract

Dynamic enhanced magnetic resonance imaging has been used to assess tumor angiogenesis in osteosarcoma. Vascular endothelial growth factor has been shown to correlate with pulmonary metastasis and a poor prognosis in osteosarcoma. The purpose of this investigation was to determine whether vascular endothelial growth factor expression in osteosarcoma correlates with vascular permeability detected by dynamic enhanced magnetic resonance imaging and to explore the role of dynamic enhanced magnetic resonance imaging as a noninvasive means of assessing tumor angiogenic activity. Fifty-five osteosarcoma patients with osteosarcoma enrolled in a treatment protocol that included dynamic enhanced magnetic resonance imaging. In 15 patients, tumor tissues were available for vascular endothelial growth factor immunohistochemical studies. A two-compartment model used the exchange rate constants (kep) between the plasma and tumor compartments to quantify vascular permeability during dynamic magnetic resonance imaging studies. Immunohistochemical staining for vascular endothelial growth factor was graded according to the intensity and number of positively stained cells. Vascular endothelial growth factor-positive tumors showed higher mean vascular permeability when compared with vascular endothelial growth factor-negative tumors. Vascular permeability also correlated with increasing vascular endothelial growth factor expression. The preliminary results in this study show an association between vascular endothelial growth factor and dynamic MR signal enhancement in osteosarcoma. Dynamic enhanced magnetic resonance imaging should be investigated as a means to prognosticate osteosarcoma patients with osteosarcoma according to their tumor angiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15346048     DOI: 10.1097/01.blo.0000141492.52166.20

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  8 in total

Review 1.  Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma.

Authors:  Ali S Arbab
Journal:  Histol Histopathol       Date:  2012-05       Impact factor: 2.303

2.  Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.

Authors:  Mesalie Feleke; Wenyu Feng; Dezhi Song; Hengyuan Li; Emel Rothzerg; Qingjun Wei; Sulev Kõks; David Wood; Yun Liu; Jiake Xu
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-13

Review 3.  Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques.

Authors:  Laura M Fayad; Michael A Jacobs; Xin Wang; John A Carrino; David A Bluemke
Journal:  Radiology       Date:  2012-11       Impact factor: 11.105

Review 4.  Imaging hemodynamics.

Authors:  Dominique Jennings; Natarajan Raghunand; Robert J Gillies
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

5.  Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.

Authors:  Ayesha Abdeen; Alexander J Chou; John H Healey; Chand Khanna; Tanasa S Osborne; Stephen M Hewitt; Mimi Kim; Dan Wang; Karen Moody; Richard Gorlick
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

Review 6.  Giant cell tumor of the uterus: case report and response to chemotherapy.

Authors:  Keith M Skubitz; J Carlos Manivel
Journal:  BMC Cancer       Date:  2007-03-14       Impact factor: 4.430

7.  Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies.

Authors:  Ricardo Gehrke Becker; Carlos Roberto Galia; Sandra Morini; Cristiano Ribeiro Viana
Journal:  Acta Ortop Bras       Date:  2013-07       Impact factor: 0.513

8.  Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

Authors:  J Guo; J O Glass; M B McCarville; B L Shulkin; V M Daryani; C F Stewart; J Wu; S Mao; J R Dwek; L M Fayad; J E Madewell; F Navid; N C Daw; W E Reddick
Journal:  Br J Cancer       Date:  2015-10-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.